IMI2 Project IM2PACT: Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics into the brain
A new consortium of 27 international partners from academia, industry, and small and medium enterprises, aims to tackle the unmet challenge of discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative and metabolic diseases. The blood-brain barrier is a protective layer between the brain’s blood capillaries and the cells that make up brain tissue. This barrier provides a defence against the pathogens and toxins that may be in our blood, allowing very few molecules to pass through. It can also prevent many drugs from passing across into the brain, and this presents a major problem in treating neurological conditions and metabolic diseases, especially when using antibody therapies. On the other hand, several neurological diseases could originate from a dysfunctional blood-brain barrier. The funding from the Innovative Medicines Initiative (IMI) to the IM2PACT consortium will allow this public-private partnership, which includes leading international experts in the field, to facilitate the development of drugs to treat neurological disorders by:
- discovering and developing innovative and effective brain transport mechanisms
- establishing and characterising blood-brain barrier models with good predictability in health and disease
- identifying translational read-outs closer to the pathogenesis of neurodegeneration and mimicking altered blood-brain barrierunder disease conditions
- in-depth understanding of the biology of the blood-brain barrier and characterisation of various pathophysiological mechanisms across the blood-brain barrier.
IM2PACT will foster the development of disease-modifying treatment in a setting of personalised medicine. For more details visit the web page: http://im2pact.org/about/about-im2pact/